製薬用契約開発製造機構(CDMO)の世界市場2019年-2027年

◆英語タイトル:Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Global Market Outlook (2019-2027)
◆商品コード:SMRC21FB255
◆発行会社(リサーチ会社):Stratistics MRC
◆発行日:2020年10月
◆ページ数:約150 
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥473,100見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥855,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Stratistics MRC社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートは、世界の製薬用契約開発製造機構(CDMO)市場規模について調査し、エグゼクティブサマリー、序論、市場動向分析、ファイブフォース分析、研究フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV、前臨床)分析、サービス種類別(医薬品製造サービス、生物製剤製造サービス、医薬品開発サービス)分析、エンドユーザー別(中小規模製薬会社、ビッグファーマ、ジェネリック製薬会社)分析、地域別分析、主要な市場開拓、企業情報など、以下の構成でまとめております。
・エグゼクティブサマリー
・序論
・市場動向分析
・ファイブフォース分析
・世界の製薬用契約開発製造機構(CDMO)市場規模:研究フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV、前臨床)
・世界の製薬用契約開発製造機構(CDMO)市場規模:サービス種類別(医薬品製造サービス、生物製剤製造サービス、医薬品開発サービス)
・世界の製薬用契約開発製造機構(CDMO)市場規模:エンドユーザー別(中小規模製薬会社、ビッグファーマ、ジェネリック製薬会社)
・世界の製薬用契約開発製造機構(CDMO)市場規模:地域別
・主要な市場開拓
・企業情報
【レポートの概要】

According to Stratistics MRC, the Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is accounted for $148.50 billion in 2019 and is expected to reach $298.07 billion by 2027 growing at a CAGR of 9.1% during the forecast period. Some of the key factors propelling the market growth include growing demand for generic medicines and biologics, growing need for state-of-the-art processes and production technologies, advent of contract development & manufacturing organization (CDMO) model, and growing investment in R&D. However, stringent government regulations are likely to hamper the market.

The contract development and manufacturing organization (CDMO) industry had begun decades ago as a niche business by offering specialty services and manufacturing capacities to pharmaceutical companies. CDMOs also play a critical role in offering additional capacities and mitigate the risk of supply shortages by providing additional manufacturing and development sites and backup facilities. Issues regarding documentation and quality of drug manufacturing process during regulatory reviews can lead to delay in marketing authorization. Therefore for pharmaceutical companies, a prompt quality standard with proven reliability is a definitive key for outsourcing to CDMOs.

By service type, pharmaceutical manufacturing services segment is projected to grow at the lucrative rate during the forecast period, due to the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, growing demand for generic drugs, high cost of operations, and lack of in-house manufacturing capacity.

On the basis of geography, Asia-Pacific is expected to witness the significant market growth during the forecast period, owing to the low cost offered by the region, as compared to the United States and other developed economies. Additionally, growing incidences of chronic and lifestyle diseases, such as diabetes and heart disease, coupled with ease of patient recruitment and availability of expertise for clinical trials, are few driving factors boosting growth in the region. With the increasing privatization of clinical trials, there has been an increase in the outsourcing of research processes in developing regions like China and India.

Some of the key players in Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market include Famar SA, Boehringer Ingelheim Group, Catalent Inc., Pfizer CentreSource, CMIC Holdings Co. Ltd, Aenova Holding GmbH, Baxter Biopharma Solutions, Syneos Health Inc., Lonza Group , Patheon Inc., Novotech Pty Ltd, Covance Inc., Recipharm AB , SGS SA (SGS Life Sciences), Jubilant Life Sciences Ltd, Samsung Bioepis Co. Ltd, IQVIA Holdings Inc., Quanticate Ltd, PAREXEL International Corporation, and WuXi AppTec Inc.

Research Phases Covered:
• Phase I
• Phase II
• Phase III
• Phase IV
• Pre-clinical

Service Types Covered:
• Pharmaceutical Manufacturing Services
• Biologics Manufacturing Services
• Drug Development Services

End Users Covered:
• Small & Mid-size Pharma
• Big Pharma
• Generic Pharmaceutical Companies

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
France
Italy
UK
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client’s interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

【レポートの目次】

1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Research Phase
5.1 Introduction
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV
5.6 Pre-clinical
6 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Service Type
6.1 Introduction
6.2 Pharmaceutical Manufacturing Services
6.2.1 Secondary Packaging
6.2.2 Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing
6.2.2.1 Liquid Dose Formulation
6.2.2.2 Parenteral/Injectable Dose Formulation
6.2.2.3 Solid Dose Formulation
6.2.2.4 Tablet Manufacturing Services
6.2.2.5 Capsule Manufacturing Services
6.2.3 Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing
6.3 Biologics Manufacturing Services
6.3.1 Biologics API Manufacturing
6.3.2 Biologics FDF Manufacturing
6.4 Drug Development Services
7 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By End User
7.1 Introduction
7.2 Small & Mid-size Pharma
7.3 Big Pharma
7.4 Generic Pharmaceutical Companies
8 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Famar SA
10.2 Boehringer Ingelheim Group
10.3 Catalent Inc.
10.4 Pfizer CentreSource
10.5 CMIC Holdings Co. Ltd
10.6 Aenova Holding GmbH
10.7 Baxter Biopharma Solutions
10.8 Syneos Health Inc.
10.9 Lonza Group
10.10 Patheon Inc.
10.11 Novotech Pty Ltd
10.12 Covance Inc.
10.13 Recipharm AB
10.14 SGS SA (SGS Life Sciences)
10.15 Jubilant Life Sciences Ltd
10.16 Samsung Bioepis Co. Ltd
10.17 IQVIA Holdings Inc.
10.18 Quanticate Ltd
10.19 PAREXEL International Corporation
10.20 WuXi AppTec Inc.



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[製薬用契約開発製造機構(CDMO)の世界市場2019年-2027年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆